

1.1–1.5

## Problem definition

Understand the clinical background to accurately define the problem.

- Domain expertise (e.g. clinical pathway)
- Population (e.g., inclusion criteria)
- Gold standard (e.g., bacteremia, sepsis)
- Aim (e.g. diagnosis, prediction)

6.1–6.6

## Miscellaneous

- Cost-sensitive analysis
- Data availability
- Code availability
- Model availability
- Live demo

5.1–5.7

## Deployment

- Legal and regulatory compliance
- Resources required
- Communication and transparency
- Establish a feedback loop
- Deployment and integration (e.g. human centred)
- Continuous monitoring and updates
- Patient diversity and bias

4.11–4.16

## Performance evaluation

- Standard metrics (e.g., ROC, PR, SENS, SPEC)
- Further analysis
  - cut-off thresholds
  - feature importance
  - behaviour for different subpopulations (e.g., age, ward, ethnicity)
  - behaviour for different prevalence levels
  - behaviour for different levels of missing data
- Domain specific metrics and clinical relevance (e.g., alert fatigue)
- Understand the economic impact (e.g., costs)
- Fairness, bias and ethical considerations

4.8–4.10

## Model configuration

- Regularization
- Normalization
- Hyperparameter tuning: employ automated methods such as grid-search or bayesian optimization.

4.7

## Data splitting

- Split the data into train, validation and a hold-out test sets.
- Consider time-aware splits to replicatemodel's usage as it would occur in a clinical setting.
- Use cross-validation

2.1–2.4

## Data collection

- Relevance
- Availability
- Quality
- Frequency of updates
- Resource requirements
- Setting
- Invasiveness
- Turnaround time
- Cost

2.1–2.4

## Data sources

- History (e.g. comorbidities)
- Demographics (e.g., age, gender)
- Management (e.g., ward, LOS)
- Organ support (e.g., ventilation)
- Symptoms (e.g., rash, bleeding)
- Vital signs (e.g., BT, HR, RR, SBP)
- Biomarkers (e.g., WBC, PLT, CRP)
- Medication (e.g., antimicrobials)
- Other (e.g., blood culture, X-Ray)

## Data leakage

2.5

- Target: information of the targeted leaked into the training process
- Time: future observations used to predict past events

3.2

Start with a **statistical** approach using descriptive statistics, correlation analysis, clinical scoring systems and/or survival analysis.

3.3

Continue with **traditional** machine learning approaches which are well established, facilitating interpretability and adoption (e.g. LR, DTC, RFC, SVM)

3.4

Explore **time series** approaches when data volume and quality allows and define clearly look-back and look-ahead settings (e.g. ARIMA, GRU, RNN, LSTM, ATTN)

3.5

Will an **ensemble** boost performance?

3.6–3.10

Consider **aspects** such as...

- Complexity
- Interpretability
- Adoption
- Adaptation
- Data requirements (volume, quality)
- Computational resources
- Tendency to overfit
- Consider implementation
- Data governance and privacy
- Data collection and storage
- Data annotation, labeling, ...

4.1–4.2

## Data cleaning

- Consider the study design requirements
- Discard duplicates, errors, ...
- Discard using the domain knowledge
- Discard outliers (e.g., physiological range)

4.3

## Class imbalance

Acknowledge, describe and/or address class imbalance. Use appropriate metrics to evaluate model performance.

4.4

## Imputation

- Cross-sectional data (e.g., median)
- Timeseries (e.g., ffill + median)
- Irregularly sampled timeseries (MGP)

4.6

## Feature engineering

- Domain knowledge (e.g., X/Y ratio)
- Categorization (e.g., low, medium, high)
- Stat. measures (e.g., min, max, range)
- Stat. momentums (e.g., mean, std)
- Temporal differences (e.g., t, t1–t, t2–t)
- Rolling statistics (e.g., mean HR over 1h)
- Time since the last event (e.g., )
- Frequency encodings (e.g., DFT)
- Complex abstractions
- Dimensionality reduction (e.g., PCA)
- Indicator variables (e.g., missing mask)